This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Jacobson-Kram, D. Articles by Jacobs, A. Search for Related Content PubMed PubMed Citation Articles by Jacobson-Kram, D. Articles by Jacobs, A. Social Bookmarking                         What's this?

Use of Genotoxicity Data to Support Clinical Trials or Positive Genetox Findings on a Candidate Pharmaceutical or Impurity .... Now What?

Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, USA

Correspondence: Address correspondence to David Jacobson-Kram, PhD, DABT, Associate Director for Pharmacology and Toxicology, Office of New Drugs, Center for Drug Evaluation and Research, U.S. FDA, HFD-024, 5515 Security Lane, Rockville, MD 20852, USA. E-mail:jacobsonkram{at}cder.fda.gov

Results from carcinogenicity studies are generally not available for drugs until the time of approval. Many people, including healthy volunteers are often exposed to pharmacologically active doses of the drug before carcinogenicity results are available. The Food and Drug Administration (FDA) Center for Drug Evaluation and Research uses results of genetic toxicology studies as a surrogate for carcinogenicity during the drug development phase (clinical trials). A number of issues are considered in deciding whether drugs that give positive results in genetic toxicology studies can be given to subjects in clinical trials. These relate to the drug indication, the target population, duration of treatment, and importance of the drug. In general, single-dose clinical studies are permitted regardless of the genetox results. In situations where a genetic toxicology assay showed a positive result, some review divisions have asked sponsors to perform a Syrian hamster embryo (SHE) cell transformation assay or a p53 carcinogenicity study prior to allowing repeat-dose clinical trials to proceed. This paper discusses alternatives to SHE cell and p53 assays when faced with a positive result in a genetic toxicology assay. In addition, this paper discusses factors to consider when setting limits for genotoxic impurities in drug substances and products.

Key Words: Carcinogenicity • Clinical Trials • Genotoxic Impurities • Genotoxicity • Pharmaceutical Safety • Weight-of-Evidence

International Journal of Toxicology, Vol. 24, No. 3, 129-134 (2005)
DOI: 10.1080/10915810590952933


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Ellinger-Ziegelbauer, J. M. Fostel, C. Aruga, D. Bauer, E. Boitier, S. Deng, D. Dickinson, A.-C. Le Fevre, A. J. Fornace Jr, O. Grenet, et al. Characterization and Interlaboratory Comparison of a Gene Expression Signature for Differentiating Genotoxic Mechanisms Toxicol. Sci., August 1, 2009; 110(2): 341 - 352. [Abstract] [Full Text] [PDF]

				W. W. Ku, J. Aubrecht, R. J. Mauthe, R. H. Schiestl, and A. J. Fornace Jr Genetic Toxicity Assessment: Employing the Best Science for Human Safety Evaluation Part VII: Why Not Start with a Single Test: A Transformational Alternative to Genotoxicity Hazard and Risk Assessment Toxicol. Sci., September 1, 2007; 99(1): 20 - 25. [Abstract] [Full Text] [PDF]